264 related articles for article (PubMed ID: 32349579)
1. COVID-19: the use of immunotherapy in metastatic lung cancer.
Davis AP; Boyer M; Lee JH; Kao SC
Immunotherapy; 2020 Jun; 12(8):545-548. PubMed ID: 32349579
[No Abstract] [Full Text] [Related]
2. Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
Chang HL; Wei PJ; Wu KL; Huang HL; Yang CJ
Lung Cancer; 2020 Aug; 146():376-377. PubMed ID: 32576385
[No Abstract] [Full Text] [Related]
3. COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy.
da Costa CM; de Souza ZS; Real Salgues AC; Harada G; Marino Rodrigues Ayres PP; Vieira Nunes DB; Katz A; Munhoz RR
Immunotherapy; 2020 Oct; 12(15):1133-1138. PubMed ID: 32900245
[No Abstract] [Full Text] [Related]
4. Clinical courses and outcomes of five patients with primary lung cancer surgically treated while affected by Severe acute respiratory syndrome coronavirus 2.
Gonfiotti A; Gatteschi L; Salvicchi A; Bongiolatti S; Lavorini F; Voltolini L
Eur J Cardiothorac Surg; 2020 Sep; 58(3):598-604. PubMed ID: 32856063
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?
Di Noia V; D'Aveni A; Squadroni M; Beretta GD; Ceresoli GL
Lung Cancer; 2020 Jul; 145():208-210. PubMed ID: 32439211
[No Abstract] [Full Text] [Related]
6. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.
Bersanelli M
Immunotherapy; 2020 Apr; 12(5):269-273. PubMed ID: 32212881
[No Abstract] [Full Text] [Related]
7. [Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of coronavirus disease 2019 (Trial version)].
;
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Apr; 43(4):297-301. PubMed ID: 32125132
[TBL] [Abstract][Full Text] [Related]
8. [Not Available].
Fabre E; Pécuchet N; Cadranel J
Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y
Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.
Wu Q; Chu Q; Zhang H; Yang B; He X; Zhong Y; Yuan X; Chua MLK; Xie C
Cancer Commun (Lond); 2020 Aug; 40(8):374-379. PubMed ID: 32666636
[No Abstract] [Full Text] [Related]
11. Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature.
L Gemmill JA; Sher A
Cancer Invest; 2020 Jul; 38(6):365-371. PubMed ID: 32559143
[TBL] [Abstract][Full Text] [Related]
12. Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment.
Rossi E; Schinzari G; Tortora G
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32699182
[TBL] [Abstract][Full Text] [Related]
13. Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.
Yekedüz E; Dursun B; Aydın GÇ; Yazgan SC; Öztürk HH; Azap A; Utkan G; Ürün Y
J Oncol Pharm Pract; 2020 Jul; 26(5):1289-1294. PubMed ID: 32423324
[TBL] [Abstract][Full Text] [Related]
14. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
Leonardi GC; Oxnard GR; Haas A; Lang JP; Williams JS; Awad MM
J Immunother; 2017; 40(6):249-251. PubMed ID: 28557813
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China.
Xie J; Tong Z; Guan X; Du B; Qiu H
JAMA Netw Open; 2020 Apr; 3(4):e205619. PubMed ID: 32275319
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary embolism and acro-ischemia in a lung cancer patient with COVID-19.
González Del Portillo E; Pérez-Romasanta LA
Med Clin (Barc); 2020 Sep; 155(5):226-227. PubMed ID: 32586671
[No Abstract] [Full Text] [Related]
17. The treatment and outcome of a pulmonary sarcomatoid carcinoma patient infected with SARS-CoV-2.
Wang K; Liu Y; Hu T; Liu Y; Liu C
Lung Cancer; 2020 Aug; 146():373-375. PubMed ID: 32563532
[No Abstract] [Full Text] [Related]
18. Patients With Lung Cancer Have High Susceptibility of COVID-19: A Retrospective Study in Wuhan, China.
Dai MY; Chen Z; Leng Y; Wu M; Liu Y; Zhou F; Ming C; Shao N; Liu M; Cai H
Cancer Control; 2020; 27(1):1073274820960467. PubMed ID: 32938231
[TBL] [Abstract][Full Text] [Related]
19. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
20. PD-1-targeted immunotherapy: recent clinical findings.
Brahmer JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
